Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART

NCT04612452 is registered in ClinicalTrials.gov with University of Bern as lead sponsor.

NCT NCT04612452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04612452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART
Lead sponsor
University of Bern
Phase
Observational
Overall status
Completed
Start date
November 5, 2019
Completion date
March 22, 2023
Enrollment
2,820 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

drug resistancy, hiv, virologic failure